Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Citing Choice-of-Law Issues, Appeals Court Reverses Plaintiff Verdict in Accutane Case
An appeals court has reversed a $25 million verdict against Hoffmann-La Roche Inc. and Roche Laboratories in the case of a man who alleged he developed Crohn's disease after using the company's acne drug, Accutane. New Jersey's Appellate Division ruled Aug. 11 in McCarrell v. Hoffmann-La Roche that the filing of the suit was untimely because the trial court erred in applying New Jersey's statute of limitations to the case rather than the law of the plaintiff's home state, Alabama. This is the second reversal in this case; the first plaintiff verdict was rendered in 2007, but it was also thrown out on appeal.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
Why is it that those who are best skilled at advocating for others are ill-equipped at advocating for their own skills and what to do about it?
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
Active reading comprises many daily tasks lawyers engage in, including highlighting, annotating, note taking, comparing and searching texts. It demands more than flipping or turning pages.
With trillions of dollars to keep watch over, the last thing we need is the distraction of costly litigation brought on by patent assertion entities (PAEs or "patent trolls"), companies that don't make any products but instead seek royalties by asserting their patents against those who do make products.